JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

News

JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

Posted: 01/09/2020
News Articles 2020

JenaValve Pericardial TAVR System is the First Transcatheter Device to Achieve Breakthrough Device Designation; Prioritizes Premarket Approval Development Path for Severe Aortic Regurgitation Indication

Most Viewed Pages

First-in-Human Percutaneous Removal of Left Atrial Appendage Occlusion Devices With a Novel Retrieval System

Technology viewpoint: Evolution in PCI: The next major advance in implant technology to restore vessel function

Watchful Waiting Strategy in Extensive Iatrogenic Aortic Dissection Complicating Percutaneous Coronary Intervention

Episode 14 | Short DAPT the Ultimate DAPT study and the Guidelines

Preventative PCI with Optimal Medical Therapy Reduces Long-Term MACE in Patients with Non-Flow-Limiting Vulnerable Plaques: PREVENT Trial

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

News

JenaValve Transcatheter Aortic Valve Replacement (TAVR) System Designated by FDA as Breakthrough Device

Most Viewed Pages

Explore the Site

Stay Connected